Sorrento acquires lymphatic delivery technology platform from Kimberly-Clark

This article was originally published here

Sorrento Therapeutics has acquired Kimberly-Clark’s Sofusa lymphatic delivery technology platform for targeted biopharmaceuticals, particularly, the immune checkpoint inhibitors like anti-PD-1, CTLA4, CD47 antibodies and other I-O antibodies.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply